Recognising sepsis in the non-ICU patient
Sepsis is a time-critical condition that requires prompt recognition and rapid initiation of treatment and pharmacists need to be able to recognise the deteriorating patient and ensure appropriate treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 16, 2015 Category: Drugs & Pharmacology Authors: ebercott Tags: Infectious Disease Featured Articles Source Type: news
UKCPA Introduction to Pharmaceutical Care Course taking place on 20–21 February, in Manchester
The Introduction to Pharmaceutical Care Course is an intensive programme of workshops specially designed for:
Pre-registration pharmacy students in primary and secondary care.
Newly qualified pharmacists wanting a foundation course prior to starting a clinical diploma.
Pharmacists returning to practice who wish to update their clinical skills.
Overseas pharmacists new to clinical practice. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 11, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick UK Conference and Symposia Introduction to Pharmaceutical Care Course Latest News ukcpa Source Type: news
New training to help pharmacists improve the health of mothers and children
As the World Health Organization’s Executive Board discusses maternal, newborn and child health in Geneva, the International Pharmaceutical Federation’s Community Pharmacy Section (CPS) is launching a series of four free webinars to support pharmacists’ efforts in this area. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 2, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News European Conferences and Symposia child health CPS fip Latest News maternal health newborn health Source Type: news
UKCPA events in February and March
An intensive programme of workshops specially designed for pre-registration pharmacy students in primary and secondary care, newly qualified pharmacists wanting a foundation course prior to starting a clinical diploma, pharmacists returning to practice who wish to update their clinical skills and overseas pharmacists new to clinical practice. (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 2, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News UK Conference and Symposia cardiology critical care events Latest News masterclasses pharmaceutical care ukcpa Source Type: news
Expert panel recommends new approaches to management of ADPKD
A report has been published by the European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, as well as patient group representatives, dedicated to improving the health and quality of life of people with autosomal dominant polycystic kidney disease (ADPKD) – a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 30, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Practical therapeutics Nephrology Patient care Autosomal dominant polycystic kidney disease cysts EAF economic impact hypertension Latest News Source Type: news
Accord Healthcare launches their first biopharmaceutical product in Europe: Accofil® (filgrastim)
Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Haematology Oncology biopharmaceutical chemotherapy induced neutropenia filgrastim hiv Latest News peripheral blood progenitor cells Source Type: news
NICE recommends Xarelto® as a treatment option for reducing secondary events in ACS
The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to ...
Source: Pharmacy Europe - January 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness Industry News Cardiovascular medicine Legislation & regulation Patient care acs antiplatelet therapy ATLAS ACS 2 TIMI 51 Latest News TIA Xaltero Source Type: news
Once-daily treatment option for people with type 2 diabetes and moderate CKD in the UK
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 20, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Diabetes Endochrine Disorders Nephrology Patient care glucose control kidney disease Latest News liraglutide renal impairment type 2 diabetes victoza Source Type: news
Celgene’s Otezla® (apremilast) receives European marketing authorisation
Celgene UK announced that the European Commission has licenced Otezla®, the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (2)
For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).
Alone or in combination with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis in adult patients who have had an inadequate r...
Source: Pharmacy Europe - January 16, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Dermatology Rheumatology Patient care chronic plaque psoriasis DMARD Latest News PDE4 inhibitor psoriatic arthritis PUVA Source Type: news
UK specialist recommended for latest Ebola decontamination
Following a recent Ebola virus disease (EVD) patient being discharged from a Glasgow hospital and transferred by military plane to a specialist north London centre, Bioquell technology was again called into action. The Hampshire-based company was commissioned to deploy its hydrogen peroxide vapour (HPV) technology - the gold standard in bio-decontamination. The firm’s HPV process kills 99.9999% of pathogens, eliminating doubt by destroying biological threats in healthcare and life science environments. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 13, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Latest News Source Type: news
EAHP’s New Year appeal to Europe
At the start of the new European Commission’s first full year of operation, the European Association of Hospital Pharmacists (EAHP) has issued a call to EU policy makers to make 2015 a year of action in meeting the antimicrobial resistance challenge. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 9, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Infectious Disease Policy & practice antimicrobial resistance eahp european commission Latest News Source Type: news
Shield Therapeutics publishes Feraccru Phase III trial in Inflammatory Bowel Disease Journal
Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals announced the online publication of the manuscript of the AEGIS Feraccru (ST10, ferric maltol) Phase III pivotal study in the latest edition of the Inflammatory Bowel Disease Journal, the official journal of the Crohn’s and Colitis Foundation of America. (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 9, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology feraccru ferric maltol haemoglobin inflammatory bowel disease Latest News publication Source Type: news
Shield Therapeutics announces review of the marketing authorisation application for Feraccru®
Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals, announced the recent acceptance for review by the European Medicines Agency (EMA) of the marketing authorisation application (MAA) for Feraccru (ST10, ferric maltol). (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 7, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Haematology Policy practice anaemia feraccru ferric maltol haemoglobin hospital pharmaceuticals Latest News Source Type: news
Orphan medicine, Ramucirumab (Cyramza®), provides long-awaited advance for difficult to treat stomach cancer
First approved therapy specifically indicated for second-line advanced stomach and gastro-oesophageal junction cancer receives marketing authorisation in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 22, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1–17 years with diabetes. Once the European Commission approves the licence extension, physicians in the European Union will be able to prescribe insulin degludec to children and adolescents aged 1–17 with type 1 and type 2 diabetes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 19, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Diabetes Endochrine Disorders chmp GLP-1 receptor agonists hypoglycaemia insulin degludec/detemir Latest News Tresiba Source Type: news
